Human Factor VIII Concentrate - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510242653

Publication Date:

October 17, 2024

Pages:

146

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Complementary therapy for prevention and treatment of hemophilia A acquired coagulation factor 鈪� deficiency and von Willebrand's disease
The global market for Human Factor VIII Concentrate was estimated to be worth US$ 185 million in 2023 and is forecast to a readjusted size of US$ 242.9 million by 2030 with a CAGR of 4.0% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Factor VIII Concentrate, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Human Factor VIII Concentrate by region & country, by Type, and by Application.
The Human Factor VIII Concentrate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Factor VIII Concentrate.
麻豆原创 Segmentation
By Company
Pfizer
Novo Nordisk A/S
Shire (Baxter)
Bayer
GC Pharma
Shanghai Raas Corp
Hualan Biological
Shandong Taibang Biological Products
Shanghai Xinxing Medicine
SinoCell Tech
CSL
Grifols
Biogen
Octapharma
NovoNordisk
Segment by Type:
Blood Extraction
Recombine
Segment by Application
Congenital Coagulation Factor VIII Deficiency
Acquired Factor VIII Deficiency
Von Willebrand's Disease
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Human Factor VIII Concentrate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Human Factor VIII Concentrate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Human Factor VIII Concentrate in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Human Factor VIII Concentrate Product Introduction
1.2 Global Human Factor VIII Concentrate 麻豆原创 Size Forecast
1.2.1 Global Human Factor VIII Concentrate Sales Value (2019-2030)
1.2.2 Global Human Factor VIII Concentrate Sales Volume (2019-2030)
1.2.3 Global Human Factor VIII Concentrate Sales Price (2019-2030)
1.3 Human Factor VIII Concentrate 麻豆原创 Trends & Drivers
1.3.1 Human Factor VIII Concentrate Industry Trends
1.3.2 Human Factor VIII Concentrate 麻豆原创 Drivers & Opportunity
1.3.3 Human Factor VIII Concentrate 麻豆原创 Challenges
1.3.4 Human Factor VIII Concentrate 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Human Factor VIII Concentrate Players Revenue Ranking (2023)
2.2 Global Human Factor VIII Concentrate Revenue by Company (2019-2024)
2.3 Global Human Factor VIII Concentrate Players Sales Volume Ranking (2023)
2.4 Global Human Factor VIII Concentrate Sales Volume by Company Players (2019-2024)
2.5 Global Human Factor VIII Concentrate Average Price by Company (2019-2024)
2.6 Key Manufacturers Human Factor VIII Concentrate Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Human Factor VIII Concentrate Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Human Factor VIII Concentrate
2.9 Human Factor VIII Concentrate 麻豆原创 Competitive Analysis
2.9.1 Human Factor VIII Concentrate 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Human Factor VIII Concentrate Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Factor VIII Concentrate as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Blood Extraction
3.1.2 Recombine
3.2 Global Human Factor VIII Concentrate Sales Value by Type
3.2.1 Global Human Factor VIII Concentrate Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Human Factor VIII Concentrate Sales Value, by Type (2019-2030)
3.2.3 Global Human Factor VIII Concentrate Sales Value, by Type (%) (2019-2030)
3.3 Global Human Factor VIII Concentrate Sales Volume by Type
3.3.1 Global Human Factor VIII Concentrate Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Human Factor VIII Concentrate Sales Volume, by Type (2019-2030)
3.3.3 Global Human Factor VIII Concentrate Sales Volume, by Type (%) (2019-2030)
3.4 Global Human Factor VIII Concentrate Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Congenital Coagulation Factor VIII Deficiency
4.1.2 Acquired Factor VIII Deficiency
4.1.3 Von Willebrand's Disease
4.2 Global Human Factor VIII Concentrate Sales Value by Application
4.2.1 Global Human Factor VIII Concentrate Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Human Factor VIII Concentrate Sales Value, by Application (2019-2030)
4.2.3 Global Human Factor VIII Concentrate Sales Value, by Application (%) (2019-2030)
4.3 Global Human Factor VIII Concentrate Sales Volume by Application
4.3.1 Global Human Factor VIII Concentrate Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Human Factor VIII Concentrate Sales Volume, by Application (2019-2030)
4.3.3 Global Human Factor VIII Concentrate Sales Volume, by Application (%) (2019-2030)
4.4 Global Human Factor VIII Concentrate Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Human Factor VIII Concentrate Sales Value by Region
5.1.1 Global Human Factor VIII Concentrate Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Human Factor VIII Concentrate Sales Value by Region (2019-2024)
5.1.3 Global Human Factor VIII Concentrate Sales Value by Region (2025-2030)
5.1.4 Global Human Factor VIII Concentrate Sales Value by Region (%), (2019-2030)
5.2 Global Human Factor VIII Concentrate Sales Volume by Region
5.2.1 Global Human Factor VIII Concentrate Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Human Factor VIII Concentrate Sales Volume by Region (2019-2024)
5.2.3 Global Human Factor VIII Concentrate Sales Volume by Region (2025-2030)
5.2.4 Global Human Factor VIII Concentrate Sales Volume by Region (%), (2019-2030)
5.3 Global Human Factor VIII Concentrate Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Human Factor VIII Concentrate Sales Value, 2019-2030
5.4.2 North America Human Factor VIII Concentrate Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Human Factor VIII Concentrate Sales Value, 2019-2030
5.5.2 Europe Human Factor VIII Concentrate Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Human Factor VIII Concentrate Sales Value, 2019-2030
5.6.2 Asia Pacific Human Factor VIII Concentrate Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Human Factor VIII Concentrate Sales Value, 2019-2030
5.7.2 South America Human Factor VIII Concentrate Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Human Factor VIII Concentrate Sales Value, 2019-2030
5.8.2 Middle East & Africa Human Factor VIII Concentrate Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Human Factor VIII Concentrate Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Human Factor VIII Concentrate Sales Value
6.2.1 Key Countries/Regions Human Factor VIII Concentrate Sales Value, 2019-2030
6.2.2 Key Countries/Regions Human Factor VIII Concentrate Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Human Factor VIII Concentrate Sales Value, 2019-2030
6.3.2 United States Human Factor VIII Concentrate Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Human Factor VIII Concentrate Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Human Factor VIII Concentrate Sales Value, 2019-2030
6.4.2 Europe Human Factor VIII Concentrate Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Human Factor VIII Concentrate Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Human Factor VIII Concentrate Sales Value, 2019-2030
6.5.2 China Human Factor VIII Concentrate Sales Value by Type (%), 2023 VS 2030
6.5.3 China Human Factor VIII Concentrate Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Human Factor VIII Concentrate Sales Value, 2019-2030
6.6.2 Japan Human Factor VIII Concentrate Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Human Factor VIII Concentrate Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Human Factor VIII Concentrate Sales Value, 2019-2030
6.7.2 South Korea Human Factor VIII Concentrate Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Human Factor VIII Concentrate Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Human Factor VIII Concentrate Sales Value, 2019-2030
6.8.2 Southeast Asia Human Factor VIII Concentrate Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Human Factor VIII Concentrate Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Human Factor VIII Concentrate Sales Value, 2019-2030
6.9.2 India Human Factor VIII Concentrate Sales Value by Type (%), 2023 VS 2030
6.9.3 India Human Factor VIII Concentrate Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Company Information
7.1.2 Pfizer Introduction and Business Overview
7.1.3 Pfizer Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Pfizer Human Factor VIII Concentrate Product Offerings
7.1.5 Pfizer Recent Development
7.2 Novo Nordisk A/S
7.2.1 Novo Nordisk A/S Company Information
7.2.2 Novo Nordisk A/S Introduction and Business Overview
7.2.3 Novo Nordisk A/S Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Novo Nordisk A/S Human Factor VIII Concentrate Product Offerings
7.2.5 Novo Nordisk A/S Recent Development
7.3 Shire (Baxter)
7.3.1 Shire (Baxter) Company Information
7.3.2 Shire (Baxter) Introduction and Business Overview
7.3.3 Shire (Baxter) Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Shire (Baxter) Human Factor VIII Concentrate Product Offerings
7.3.5 Shire (Baxter) Recent Development
7.4 Bayer
7.4.1 Bayer Company Information
7.4.2 Bayer Introduction and Business Overview
7.4.3 Bayer Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Bayer Human Factor VIII Concentrate Product Offerings
7.4.5 Bayer Recent Development
7.5 GC Pharma
7.5.1 GC Pharma Company Information
7.5.2 GC Pharma Introduction and Business Overview
7.5.3 GC Pharma Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.5.4 GC Pharma Human Factor VIII Concentrate Product Offerings
7.5.5 GC Pharma Recent Development
7.6 Shanghai Raas Corp
7.6.1 Shanghai Raas Corp Company Information
7.6.2 Shanghai Raas Corp Introduction and Business Overview
7.6.3 Shanghai Raas Corp Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Shanghai Raas Corp Human Factor VIII Concentrate Product Offerings
7.6.5 Shanghai Raas Corp Recent Development
7.7 Hualan Biological
7.7.1 Hualan Biological Company Information
7.7.2 Hualan Biological Introduction and Business Overview
7.7.3 Hualan Biological Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Hualan Biological Human Factor VIII Concentrate Product Offerings
7.7.5 Hualan Biological Recent Development
7.8 Shandong Taibang Biological Products
7.8.1 Shandong Taibang Biological Products Company Information
7.8.2 Shandong Taibang Biological Products Introduction and Business Overview
7.8.3 Shandong Taibang Biological Products Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Shandong Taibang Biological Products Human Factor VIII Concentrate Product Offerings
7.8.5 Shandong Taibang Biological Products Recent Development
7.9 Shanghai Xinxing Medicine
7.9.1 Shanghai Xinxing Medicine Company Information
7.9.2 Shanghai Xinxing Medicine Introduction and Business Overview
7.9.3 Shanghai Xinxing Medicine Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Shanghai Xinxing Medicine Human Factor VIII Concentrate Product Offerings
7.9.5 Shanghai Xinxing Medicine Recent Development
7.10 SinoCell Tech
7.10.1 SinoCell Tech Company Information
7.10.2 SinoCell Tech Introduction and Business Overview
7.10.3 SinoCell Tech Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.10.4 SinoCell Tech Human Factor VIII Concentrate Product Offerings
7.10.5 SinoCell Tech Recent Development
7.11 CSL
7.11.1 CSL Company Information
7.11.2 CSL Introduction and Business Overview
7.11.3 CSL Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.11.4 CSL Human Factor VIII Concentrate Product Offerings
7.11.5 CSL Recent Development
7.12 Grifols
7.12.1 Grifols Company Information
7.12.2 Grifols Introduction and Business Overview
7.12.3 Grifols Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Grifols Human Factor VIII Concentrate Product Offerings
7.12.5 Grifols Recent Development
7.13 Biogen
7.13.1 Biogen Company Information
7.13.2 Biogen Introduction and Business Overview
7.13.3 Biogen Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Biogen Human Factor VIII Concentrate Product Offerings
7.13.5 Biogen Recent Development
7.14 Octapharma
7.14.1 Octapharma Company Information
7.14.2 Octapharma Introduction and Business Overview
7.14.3 Octapharma Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Octapharma Human Factor VIII Concentrate Product Offerings
7.14.5 Octapharma Recent Development
7.15 NovoNordisk
7.15.1 NovoNordisk Company Information
7.15.2 NovoNordisk Introduction and Business Overview
7.15.3 NovoNordisk Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
7.15.4 NovoNordisk Human Factor VIII Concentrate Product Offerings
7.15.5 NovoNordisk Recent Development
8 Industry Chain Analysis
8.1 Human Factor VIII Concentrate Industrial Chain
8.2 Human Factor VIII Concentrate Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Human Factor VIII Concentrate Sales Model
8.5.2 Sales Channel
8.5.3 Human Factor VIII Concentrate Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Pfizer
Novo Nordisk A/S
Shire (Baxter)
Bayer
GC Pharma
Shanghai Raas Corp
Hualan Biological
Shandong Taibang Biological Products
Shanghai Xinxing Medicine
SinoCell Tech
CSL
Grifols
Biogen
Octapharma
NovoNordisk

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.